Literature DB >> 9374377

Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.

V Grégoire1, M Beauduin, J F Rosier, B De Coster, M Bruniaux, M Octave-Prignot, P Scalliet.   

Abstract

Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are however available on the effect of dFdC on normal tissue radiotolerance and on factors associated with dFdC's radiosensitization in vivo. The purpose of this study was to determine the effect of dFdC on mouse jejunum radiosensitization and to investigate the kinetics of DNA synthesis inhibition and cell cycle redistribution in the jejunal crypts as surrogates of radiosensitization in vivo. For assessment of jejunum tolerance, the mice were irradiated on the whole body with 60Co gamma rays (3.5-18 Gy single dose) with or without prior administration of dFdC (150 mg kg-1). Jejunum tolerance was evaluated by the number of regenerated crypts per circumference at 86 h after irradiation. For pharmacodynamic studies, dFdC (150 or 600 mg kg-1) was given i.p. and jejunum was harvested at various times (0-48 h), preceded by a pulse BrdUrd labelling. Labelled cells were detected by immunohistochemistry on paraffin-embedded sections. DNA synthesis was inhibited within 3 h after dFdC administration. After an early wave of apoptosis (3-6 h), DNA synthesis recovered by 6 h, and crypt cells became synchronized. At 48 h, the labelling index returned almost to background level. At a level of 40 regenerated crypts, radiosensitization was observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated. In conclusion, dFdC altered the radioresponse of the mouse jejunum in a schedule-dependent fashion. Our data tend to support the hypothesis that DNA synthesis inhibition and cell cycle redistribution are surrogates for radiosensitization. More data points are however required before a definite conclusion can be drawn.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374377      PMCID: PMC2228152          DOI: 10.1038/bjc.1997.554

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Treatment-Induced Accelerated Human Tumor Growth.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1993-04       Impact factor: 5.934

2.  2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

Authors:  J Gruber; F Geisen; R Sgonc; A Egle; A Villunger; G Boeck; G Konwalinka; R Greil
Journal:  Stem Cells       Date:  1996-05       Impact factor: 6.277

3.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

Authors:  M Nordsmark; M Overgaard; J Overgaard
Journal:  Radiother Oncol       Date:  1996-10       Impact factor: 6.280

4.  Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.

Authors:  V Grégoire; N Hunter; L Milas; W A Brock; W Plunkett; W N Hittelman
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

5.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Authors:  V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

6.  Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro.

Authors:  S Rockwell; G B Grindey
Journal:  Oncol Res       Date:  1992       Impact factor: 5.574

7.  Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients.

Authors:  R R Weichselbaum; W Dahlberg; M Beckett; T Karrison; D Miller; J Clark; T J Ervin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

8.  Radiosensitization of human tumor cells by gemcitabine in vitro.

Authors:  D S Shewach; T S Lawrence
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

Review 9.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

10.  Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

Authors:  B J Braakhuis; V W Ruiz van Haperen; E Boven; G Veerman; G J Peters
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

View more
  2 in total

1.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

2.  Coniferyl aldehyde attenuates radiation enteropathy by inhibiting cell death and promoting endothelial cell function.

Authors:  Ye-Ji Jeong; Myung Gu Jung; Yeonghoon Son; Jun-Ho Jang; Yoon-Jin Lee; Sung-Ho Kim; Young-Gyo Ko; Yun-Sil Lee; Hae-June Lee
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.